NCT00512876View on ClinicalTrials.gov

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Corneal Neovascularization
Interventions
DRUG

Bevacizumab (Avastin)

Bevacizumab 10mg/mL 1 drop BID x 3 weeks

Trial Locations (1)

20307

Walter Reed Army Medical Center, Washington D.C.

All Listed Sponsors
collaborator

Massachusetts Eye and Ear Infirmary

OTHER

lead

Walter Reed Army Medical Center

FED

NCT00512876 - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization | Biotech Hunter | Biotech Hunter